SecurityAZN / AstraZeneca Plc
InstitutionJanney Capital Management LLC
Shares645,321
Value $ 22,657,000
Related 046353AB4 / Astrazeneca 5.9% Senior Notes 9/15/17
046353AF5 / Astrazeneca Plc 1.95% 09/18/19
046353AG3 / Astrazeneca Plc 4.00% 09/18/42
046353AA6 / Astrazeneca Plc 5.40% Notes 06/01/2014
046353AD0 / Astrazeneca Plc 6.45% Senior Notes 9/15/37
98934KAB6 / Zeneca Wilmington Inc Guaranteed Debentures 7% 11/15/23

Janney Capital Management LLC reports 0.45% decrease in ownership of AZN / AstraZeneca Plc

July 24, 2018 - Janney Capital Management LLC has filed a 13F-HR form disclosing ownership of 645,321 shares of AstraZeneca Plc (NYSE:AZN) with total holdings valued at $22,657,000 USD as of June 30, 2018. Janney Capital Management LLC had filed a previous 13F-HR on April 19, 2018 disclosing 648,261 shares of AstraZeneca Plc at a value of $22,670,000 USD. This represents a change in shares of -0.45 percent and a change in value of -0.06 percent during the quarter.

Other investors with positions similar to Janney Capital Management LLC include Voya Investment Management LLC, Nwq Investment Management Company, Llc, Toron Capital Markets Inc., EverPoint Asset Management, LLC, Deutsche Bank Ag\, and Thornburg Investment Management Inc.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR ASTRAZENECA PLC ADR Common Stock 046353108 35.04 645,321 -0.45 22,657 -0.06 -103 90 0.40
2018-03-31 13F-HR ASTRAZENECA PLC ADR Common Stock 046353108 34.84 648,261 -0.69 22,670 0.08 -157 176 0.78
2017-12-31 13F-HR ASTRAZENECA PLC ADR Common Stock 046353108 34.29 652,766 -0.07 22,651 2.35 -15 536 2.42
2017-09-30 13F-HR ASTRAZENECA PLC ADR Common Stock 046353108 33.98 653,211 -2.17 22,130 -2.77 -492 -139 -0.61
2017-06-30 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 32.61 667,690 -2.13 22,761 7.14 -474 1,991 9.37
2017-03-31 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 29.23 682,222 -1.78 21,244 11.95 -362 2,630 13.86
2016-12-31 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 30.09 694,610 -5.39 18,976 -21.35 -1,192 -3,958 -16.41
2016-09-30 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 31.52 734,214 6.05 24,126 15.42 1,320 1,904 9.11
2016-06-30 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 29.17 692,355 0.09 20,902 7.31 18 1,405 7.22
2016-03-31 13F-HR/A-1 Astrazeneca PLC Spon Adr Common Stocks 046353108 31.05 691,754 1.79 19,479 -15.58 377 -3,971 -17.21
2016-03-31 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 691,754 19
2015-12-31 13F-HR/A-1 Astrazeneca PLC Spon Adr Common Stocks 046353108 32.89 679,603 -1.90 23,073 4.67 -432 1,462 6.63
2015-12-31 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 679,603 23,072,541
2015-09-30 13F-HR Astrazeneca PLC Spon Adr Common Stocks 046353108 692,750 0.00 22,043 22,043 0
2015-06-30 13F-HR Astrazeneca PLC Spon Adr Common Stock 046353108 0 -100.00 0 -100.00 0 0
2015-03-31 13F-HR/A-1 Astrazeneca PLC Spon Adr Common Stock 046353108 34,249.84 344,297 2.14 23,560,000 99,204.53 246,599 23,289,676 98,165.13
2015-03-31 13F-HR/A-2 Astrazeneca PLC Spon Adr Common Stock 046353108 34,248.86 344,297 0.00 23,560 -99.90 0 -23,536,440 -99.90
2015-03-31 13F-HR Astrazeneca PLC Spon Adr Common Stock 046353108 344,297 23,560,000
2014-12-31 13F-HR Astrazeneca PLC Spon Adr COM 046353108 70.91 337,097 4.70 23,725 3.14 1,072 -349 -1.52
2014-09-30 13F-HR Astrazeneca PLC Spon Adr COM 046353108 72.88 321,975 6.86 23,002 2.74 1,507 -894 -3.99
2014-06-30 13F-HR Astrazeneca PLC Spon Adr COM 046353108 301,292 22,389

Related SEC Filings

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AstraZeneca SEC SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o (0-1)

Related News Stories

Agios Rides on Tibsovo Approval Amid Reliance on Celgene

22h zacks
On Oct 16, we issued an updated research report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) . The company’s top line mainly consists of milestone payments and collaboration revenues on the net sales of Idhifa, which is owned by its partner Celgene Corporation (CELG - Free Report) . Its wholly owned product Tibsovo was approved by the FDA in July 2018 and holds immense commercial potential in the acute myeloid leukemia (AML) market. (9-0)

Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

2018-10-19 zacks
On Oct 16, we issued an updated research report on Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) . This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of treatments primarily addressing gastrointestinal (“GI”) diseases. The company’s sole marketed drug, Linzess, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (“CIC”). (6-1)

QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

2018-10-19 zacks
QIAGEN N.V. (QGEN - Free Report) recently announced the European launch of its next-generation multiplex gastrointestinal panel — QIAstat-Dx panel. This completely integrated molecular analysis of gastrointestinal (GI) syndromes analyzes and detects the 24 most common viral, bacterial and parasitic pathogens which can cause GI infections. (4-0)

The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke

2018-10-19 zacks
Chicago, IL –October 19, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca (AZN - Free Report) , salesforce.com (CRM - Free Report) , Mastercard (MA - Free Report) , Lam Research (LRCX - Free Report) and Koninklijke Philips (PHG - Free Report) . (12-0)

Top Analyst Reports for AstraZeneca, Salesforce & Mastercard

2018-10-19 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (5-0)



CUSIP: 046353108